Journal Article

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study

Alonso-Ruiz, Alberto, Sonderegger, Ivo, Cohen, Stanley B, Lee, Eric C, Peter, Nuala, Klimiuk, Piotr A, Assudani, Deepak

2018

Overview

ObjectiveTo demonstrate clinical equivalence of adalimumab biosimilar candidate BI 695501 with Humira.MethodsPatients with active rheumatoid arthritis on stable methotrexate were randomised to BI 695501 or Humira in a double-blind, parallel-group, equivalence study. At week 24, patients were rerandomised to continue BI 695501 or Humira, or switch from Humira to BI 695501. The coprimary endpoints were the percentage of patients achieving the American College of Rheumatology 20% response criteria (ACR20) at weeks 12 and 24. Further efficacy and safety endpoints and immunogenicity were assessed up to week 58.Results645 patients were randomised. At week 12, 67.0% and 61.1% (90% CI –0.9 to 12.7) of patients receiving BI 695501 (n=324) and Humira (n=321), respectively, achieved ACR20; at week 24 the corresponding values were 69.0% and 64.5% (95% CI –3.4 to 12.5). These differences were within prespecified margins (week 12: 90% CI (–12% to 15%); week 24: 95% CI (−15% to 15%)), demonstrating therapeutic bioequivalence. 593 patients were rerandomised at week 24. Up to week 48, mean change from baseline in Disease Activity Score 28-erythrocyte sedimentation rate and ACR20/ACR50/ACR70 response rates were similar across the switched (n=147), continuous BI 695501 (n=298) and continuous Humira (n=148) groups. Similar immunogenicity (antidrug antibodies (ADAs), ADA titres and neutralising antibodies) was seen between BI 695501 and Humira (to week 24) and across rerandomised groups (to week 48). Safety and tolerability profiles were similar between groups.ConclusionsBI 695501 demonstrated similar efficacy, safety and immunogenicity to Humira; switch from Humira to BI 695501 had no impact on efficacy, safety and immunogenicity.Trial registration number NCT02137226, Results.

• Publisher: Elsevier Limited,BMJ Publishing Group
• Subject: Adalimumab - administration & dosage / Adalimumab - adverse effects / Adalimumab - immunology / Adalimumab - therapeutic use / Adult / Aged / Aged, 80 and over / Antirheumatic Agents - administration & dosage / Antirheumatic Agents - adverse effects / Antirheumatic Agents - immunology / Antirheumatic Agents - therapeutic use / Arthritis, Rheumatoid - drug therapy / Arthritis, Rheumatoid - immunology / Bioequivalence / Biosimilar Pharmaceuticals - administration & dosage / Biosimilar Pharmaceuticals - adverse effects / Biosimilar Pharmaceuticals - therapeutic use / Blood Sedimentation / Clinical and Epidemiological Research / Clinical trials / Double-Blind Method / Drug Administration Schedule / Erythrocyte sedimentation rate / Female / Humans / Immunogenicity / Immunotherapy / Injections, Subcutaneous / Male / Methotrexate / Middle Aged / Monoclonal antibodies / Rheumatoid arthritis / Safety / Sensitivity and Specificity / Severity of Illness Index / Therapeutic Equivalency / TNF inhibitors / Voltaire (Francois Marie Arouet) (1694-1778) / Young Adult